Inovio Halts ATM Program After Raising Modest $3.2M Amid Going Concern Warning
INO is trading near its 52-week low of $1.3 (12% above the low).
Summary
Inovio Pharmaceuticals has suspended its At-The-Market (ATM) equity offering program, notifying Oppenheimer of the termination of the August 2024 ATM prospectus, effective April 1, 2026. The company raised $3.2 million by selling 1,319,644 shares under the program before its suspension. While the sales agreement remains active, no further shares will be sold until a new prospectus is filed. This development is significant given the company's recent 10-K filing, which included a going concern warning and highlighted financial and regulatory challenges. Suspending a capital-raising mechanism, even after a modest raise, could signal difficulties in attracting further capital at favorable terms or a shift in financing strategy, which is a concern for a company facing liquidity issues. Traders will be watching for any new financing announcements or updates on their capital needs.
At the time of this announcement, INO was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $120.2M. The 52-week trading range was $1.30 to $2.98. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.